Champions Oncology Share Price Today

Champions Oncology Q3FY26 Results: Services revenue up 32% to $16.6m

Champions Oncology posted record Q3FY26 services revenue of $16.6 million, up 32% YoY from $12.6 million. Total Q3FY26 revenue fell approximately 3% YoY to $16.6 million due to nil data revenue versus $4.5 million in the prior-year period. Adjusted EBITDA was positive at $575,000 for Q3FY26, marking the third consecutive quarter of positive adjusted EBITDA. Gross margin contracted to 47% from 61%; outsourced radiolabeling costs exceeded $2 million, with management noting internal execution would have pushed margin above 50%. Full-year FY26 revenue reached a record $59.4 million with services revenue up 12%, and the company ended FY26 with $4.9 million in cash and no debt.

Champions Oncology Q4FY26 Results: Revenue up 12% to $59.4 million

Record FY26 revenue of $59.4 million driven by 12% growth in core services. Full-year adjusted EBITDA turned positive at $1.6 million for the first time since FY22. Gross margin expanded to 48% annually and 51% in Q4 due to in-house radiopharma shift. Data revenue fell to $800,000 from $4.7 million as large prior-year transaction did not recur. Company ended FY26 with $4.9 million cash and no debt.

Champions Oncology Q1 Results: Adj. EPS up 400% to $0.05

Adjusted EPS rose 400% YoY to $0.05 from $0.01. Sales increased 8.84% to $15.232 million. Revenue grew from $13.995 million in the prior year quarter. Profit growth significantly outpaced top-line expansion.

Champions Oncology adds in-house SPECT/CT imaging to radiopharma platform

Champions Oncology adds in-house SPECT/CT imaging to its radiopharmaceutical platform. New capability enables longitudinal visualization of radiopharmaceutical uptake in vivo. Integration connects imaging data with terminal biodistribution and PDX tumor biology. Platform supports improved model selection and biomarker identification for sponsors. Entire workflow remains U.S.-based within existing translational oncology services.

Champions Oncology Q4 Results: Adjusted EPS beats estimates

Champions Oncology delivered a strong fourth quarter, reporting adjusted EPS of $0.01 against a $(0.05) estimate and sales of $13.835 million against a $12.886 million estimate. The results reflect an 114.29 percent improvement in EPS and an 11.98 percent year-over-year sales increase.

Champions Oncology to announce Q4 and FY26 results on July 27

Champions Oncology, Inc. will announce its financial results for the quarter and year ended April 30, 2026, on July 27, 2026. A conference call is scheduled for 4:30 P.M. ET to discuss the outcomes. Replay options will be available via phone and the company's website.